The growing consumer use of experimental peptides has outpaced the science. The FDA is considering whether to allow six popular peptides to be compounded by licensed pharmacies, a move that could create a large telehealth market but would not make the drugs FDA-approved. Because high-quality human data are limited and advisory deliberations raised conflict-of-interest concerns, the best option is to allow regulated access only alongside a one-year, federally coordinated research program led by the NIH with FDA and CDC support. That strategy would let current users continue treatment while generating evidence through randomized trials and safety monitoring.
The FDA’s Peptide Dilemma: Regulated Access Should Come With a Time-Limited Research Plan
Online clinics and wellness influencers promote experimental peptides as ways to heal injuries, reduce inflammation, improve metabolism, sharpen thinking and slow aging.getty
Short chains of amino acids called peptides have surged in popularity across fitness, longevity and wellness circles. Promoted online by clinics and influencers as treatments for injury repair, inflammation, metabolism, cognition and aging, many of these products now circulate in a large grey market—often sourced overseas where manufacturing quality, purity and content are difficult to verify.
Federal regulators face a consequential choice: whether six widely used but still experimental peptides should be added to the Section 503A Bulks List, allowing licensed compounding pharmacies to prepare them for patients under physician prescriptions. The compounds under near-final consideration are BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax.
Why the Decision Matters
The commercial stakes are significant. Analysts at Leerink Partners estimate that telehealth sales of these peptides could approach $2.2 billion by 2027 if the FDA authorizes broader access through compounding pharmacies. Yet the agency’s own staff and outside experts note a striking lack of high-quality human evidence about safety and effectiveness for these six peptides.
Evidence Gaps and Safety Questions
Most available studies are animal experiments or small, uncontrolled human trials. That evidence base cannot reliably establish efficacy or long-term safety. The absence of proof is not proof of harm—but it does mean clinicians and regulators cannot determine whether the potential benefits outweigh risks.
Process Concerns
The FDA’s Pharmacy Compounding Advisory Committee voted narrowly to recommend adding six of seven reviewed substances to the 503A Bulks List. The recommendation drew scrutiny because FDA staff highlighted insufficient evidence, and media reporting identified at least several recently added committee members with ties to peptide-related businesses or clinics, prompting concerns about potential conflicts of interest. The FDA says members underwent standard ethics reviews; supporters counter that experienced clinicians and pharmacists add practical insight.
A Better Path: Regulated Access Paired With Focused Research
The central problem is not simply yes or no. Either choice leaves major questions unanswered. A more constructive approach is to pair any expanded compounding access with a federally coordinated, time-limited research program to generate real-world evidence quickly.
Proposal: Authorize qualified compounding pharmacies to supply these peptides only as part of a one-year, NIH-led research initiative with FDA and CDC support. Existing patients could continue therapy if they consent to systematic data collection; new patients would enroll in randomized, double-blind trials targeted to specific medical indications.
That model would produce substantially more evidence in a relatively short period. After one year, regulators could review aggregated safety and efficacy data and decide whether to expand, restrict, or modify access while longer-term follow-up continues. This approach follows precedent—Medicare’s "coverage with evidence development" for certain treatments, for example—and balances patient access with rigorous evaluation.
Who Should Pay?
Companies and clinics that stand to profit from broader peptide availability should contribute to funding research. That expectation aligns with existing practices: medical-product makers already pay user fees and fund post-market safety activities that support regulatory review.
Conclusion
Millions of Americans are already obtaining unapproved peptides from overseas suppliers. Simply blocking access drives consumers to the grey market; simply opening access without evidence risks widespread use of products whose benefits and harms remain uncertain. The most responsible course is a middle path: controlled, physician-supervised access through licensed compounding pharmacies combined with a clear, time-limited federal research program to answer the critical questions of safety and effectiveness.
Help us improve.
